AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY

Degenerative Disc Disease Clinical Trial

— APROPOS  

Official title:

A Prospective Multi-Center Evaluation of a Hydraulic Expandable TLIF Cage for the Treatment of Degenerative Disc Disease of the Lumbar Spine

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02704689
• Other study ID #: 2015-L-001
• Secondary ID: 510(k) 132505 &
• Status: Terminated
• Phase: N/A
• First received: February 17, 2016
• Last updated: April 20, 2018
• Start date: June 8, 2016
• Est. completion date: January 19, 2017

Study information

• Verified date: April 2018
• Source: Stryker Spine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a post-market clinical study of the AccuLIF expandable transforaminal lumbar interbody fusion (TLIF) cage in patients requiring surgery for degenerative disc disease (DDD) with up to Grade I spondylolisthesis or retrolisthesis, at one or two levels, between L2 and S1.

Description:

Study evaluations will be evaluated pre-operatively and at 6-weeks, 3-months, 6-months, 12-months and 24-months post-operatively to assess clinical outcomes, patient reported outcomes and radiographic status.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: January 19, 2017
• Est. primary completion date: January 19, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Subject is skeletally mature and between 18 and 70 years of age.

2. DDD and up to Grade I spondylolisthesis or retrolisthesis, requiring decompression and arthrodesis at one or two contiguous levels between L2 and S1.

3. No previous surgery at the same or adjacent level (other than microdiscectomy / laminectomy) at the same or adjacent level.

4. Non-responsive to conservative (non-surgical) treatment for back pain for a minimum of 6 months.

5. Subject understands the conditions of enrollment and is willing to sign and date the Informed Consent.

6. Subject agrees to comply with visit schedule and completing study questionnaires.

Exclusion Criteria:

1. Significant instability of the spine.

2. Requires TLIF at more than 2 levels between L2 and S1.

3. Previously undergone lumbar spine surgery (other than microdiscectomy / laminectomy) at the same or adjacent level.

4. Younger than 18 years of age, or older than 70 years of age.

5. BMI of 40 or greater.

6. History of metabolic bone disease

7. Osteoporosis

8. Diabetes mellitus requiring daily insulin management.

9. Subject has any of the following:

1. Progressive neuromuscular disease; OR

2. Autoimmune disease; OR

3. Active malignancy within the last 15 years; OR

4. Active hepatitis; OR

5. AIDS, ARC, or is HIV positive; OR

6. Syringomyelia at any spinal level; OR

7. Any other condition that would interfere with the subject self -assessment of pain, function or quality of life.

10. Allergy to implant materials (titanium, titanium alloy).

11. Active systemic infection or infection localized to the site of implantation.

12. Primary or metastatic tumors involving the spine.

13. Open wounds or inadequate issue tissue coverage over the operative site.

14. History of significant mental illness or mental incapacity.

15. Pregnancy or intent to become pregnant.

16. Participating in another investigational study for a similar purpose.

17. Belongs to a vulnerable population that would compromise ability to provide informed consent or compliance with follow-up requirements.

18. Smokers unwilling to cease up to 3 months post-op or recent history of alcohol or other substance abuse within the past 2 years.

19. Workers compensation.

Related Conditions & MeSH terms

• Degenerative Disc Disease
• Intervertebral Disc Degeneration
• Retrolisthesis
• Spondylolisthesis
• Spondylolisthesis, Grade 1

Intervention

Device:
• AccuLIF expandable TLIF cage
AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.

Locations

Country	Name	City	State
United States	University of Missouri Health Care	Columbia	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Stryker Spine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-operative Radiographic Measurements to Evaluate Segmental Lordosis as Measured by Degree of Change From Pre-operative X-rays.	Post-operative radiographic measurements to evaluate segmental lordosis as measured by degree of change from pre-operative x-rays.	24 months
Primary	Pre-operative Comparison to Post-operative Radiographic Outcomes of Disc Height as Measured in mm.	Pre-operative comparison to post-operative radiographic outcomes of disc height as measured in mm.	24 months
Secondary	Surgical Outcomes: To Measure the Length of Surgery as Measured in Time of Surgery Duration.	Surgical Outcomes: To measure the length of surgery as measured in time of surgery duration.	Operative Visit
Secondary	Surgical Outcomes: To Evaluate the Length of Time Hospitalized for the Index Procedure as Measured in Days.	Surgical Outcomes: To evaluate the length of time hospitalized for the index procedure as measured in days.	Peri-op
Secondary	Surgical Outcomes: To Measure the Amount of Blood Loss at the Time of Surgery.	Surgical Outcomes: To measure the amount of blood loss at the time of surgery.	Operative Visit
Secondary	Medical Outcomes: Incidence of Complications Associated With the Procedure and/or Device.	Medical Outcomes: Incidence of complications associated with the procedure and/or device.	24 months
Secondary	Medical Outcomes: Comparison of Pre-operative Neurological Reflex Evaluations in the Lower Extremities to Post-operative Findings	Medical Outcomes: Comparison of pre-operative neurological Reflex evaluations in the lower extremities to post-operative findings	24 months
Secondary	Medical Outcomes: Comparison of Pre-operative Neurological Sensory Responses in the Lower Extremities to Post-operative Findings.	Medical Outcomes: Comparison of pre-operative neurological Sensory Responses in the lower extremities to post-operative findings.	24 months
Secondary	Medical Outcomes: Comparison of Pre-operative Neurological Motors Assessments Evaluated by Straight Leg Raise, Femoral Stretch, and Strength Assessments, to Post-operative Findings.	Medical Outcomes: Comparison of pre-operative neurological Motors assessments evaluated by Straight Leg Raise, Femoral Stretch, and Strength assessments, to post-operative findings.	24 months
Secondary	Patient Reported Outcomes: Comparison of Pre-operative Back Pain Scores to Post-operative Levels as Measured by the (Visual Analog Scale (VAS).	Patient Reported Outcomes: Comparison of pre-operative back pain scores to post-operative levels as measured by the (Visual Analog Scale (VAS).	24 months
Secondary	Patient Reported Outcomes: Oswestry Disability Index Measurements for Comparison of Pre-operative to Post-operative Evaluations.	Patient Reported Outcomes: Oswestry Disability Index measurements for comparison of pre-operative to post-operative evaluations.	24 months
Secondary	Patient Reported Outcomes: Evaluations of Quality of Life (QOL) as Measured by the SF-12.	Patient Reported Outcomes: Evaluations of Quality of Life (QOL) as measured by the SF-12.	24 months
Secondary	Radiographic Outcomes: Fusion Status Evaluated by X-ray and/or CT Assessments.	Radiographic Outcomes: Fusion status evaluated by x-ray and/or CT assessments.	24 months
Secondary	Radiographic Outcomes: Device Placement Status as Evaluated by X-ray and/or CT Imaging.	Radiographic Outcomes: Device placement status as evaluated by x-ray and/or CT imaging.	24 months